世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

エンジニアードT細胞市場:タイプ別(腫瘍浸潤リンパ球、T細胞受容体、キメラ抗原受容体)、用途別(肺がん、乳がん、大腸がん、メラノーマ、白血病、その他)、エンドユーザ別(病院、がん研究センター、クリニック) - 世界の機会分析と産業予測 2017-2023年

Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 

出版社 出版年月電子版価格 ページ数
Allied Market Research
アライドマーケットリサーチ
2018年1月US$5,370
シングルユーザライセンス
196

サマリー

この調査レポートはエンジニアードT細胞市場を分析・予測したAllied Market Researchの市場調査報告書です。

Description

T cell is a type of white blood cell, and plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient’s body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells. The global engineered T cells market was valued at $145.97 million in 2016, and is estimated to reach at $2,124.02 million by 2023, registering a CAGR of 46.5% from 2017 to 2023.

Increase in of incidence of various types of cancers and autoimmune diseases is projected to drive the growth of the engineered T cells market. In addition, advantages offered by engineered T cells therapies over traditional cancer treatments such as chemotherapy, high technological advancements, and increase access to medical insurance are expected to boost the market growth. However, high cost associated with T cells therapies and lack of awareness about T cells therapies hinder the growth of this market.

The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into chimeric antigen receptor (CAR) modified T cells, tumor infiltrating lymphocytes (TIL), and T cells receptor (TCR) modified T cells. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia, and other applications. Depending on end user, it is fragmented into hospitals, cancer research centers, and clinics. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global engineered T-cells market and the current trends and future estimations to elucidate the imminent investment pockets.
It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on end user assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type

Chimeric Antigen Receptor (CAR)
Tumor Infiltrating Lymphocytes (TIL)
T-cell Receptor (TCR)

By Application

Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Leukemia
Others

By End User

Hospitals
Cancer Research Centers
Clinics

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA

KEY PLAYERS PROFILED IN THE REPORT

Autolus Limited
Bellicum Pharmaceuticals, Inc.
Cell Medica
Elli Lilly and Company
Gilead Sciences, Inc.
Juno Therapeutics
Novartis AG
Oxford Biomedica
Pfizer Inc.
Precision Bioscience

The other players in the value chain include (profiles not included in the report)

Redmile Group
Seeking Alpha
Unum Therapeutics Inc.



目次

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. TOP WINNING STRATEGIES, BY YEAR, 2015-2017
3.2.2.2. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2017 (%)
3.2.2.3. TOP WINNING STRATEGIES, BY COMPANY, 2015-2017

3.3. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. TOP PLAYER POSITIONING, 2016
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in government expenditure for the healthcare sector
3.5.1.2. Increased access to medical insurance
3.5.1.3. Increase in geriatric population
3.5.1.4. Increase in prevalence of cancer diseases

3.5.2. Restraint

3.5.2.1. Risk of allergic reaction and limitations of the engineered T cells treatment
3.5.2.2. Stringent government regulations
3.5.2.3. High cost of engineered T cells treatment

3.5.3. Opportunity

3.5.3.1. Increase in R&D in engineered T cells
3.5.3.2. Lucrative opportunities from emerging economies

CHAPTER 4 ENGINEERED T CELLS MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast

4.3. T CELLS RECEPTOR (TCR) MODIFIED T CELLS

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast

4.4. TUMOR INFILTRATING LYMPHOCYTES

4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast

CHAPTER 5 ENGINEERED T CELLS MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. LUNG CANCER

5.2.1. Market size and forecast

5.3. BREAST CANCER

5.3.1. Market size and forecast

5.4. COLORECTAL CANCER

5.4.1. Market size and forecast

5.5. MELANOMA

5.5.1. Market size and forecast

5.6. LEUKEMIA

5.6.1. Market size and forecast

5.7. OTHERS APPLICATIONS

5.7.1. Market size and forecast

CHAPTER 6 ENGINEERED T CELLS MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITALS

6.2.1. Market size and forecast

6.3. CANCER RESEARCH CENTERS

6.3.1. Market size and forecast

6.4. CLINICS

6.4.1. Market size and forecast

CHAPTER 7 ENGINEERED T CELLS MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast
7.2.3. U.S. market size and forecast
7.2.4. Canada market size and forecast
7.2.5. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast
7.3.3. Germany market size and forecast
7.3.4. France market size and forecast
7.3.5. UK market size and forecast
7.3.6. Italy market size and forecast
7.3.7. Spain market size and forecast
7.3.8. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast
7.4.3. Japan market size and forecast
7.4.4. China market size and forecast
7.4.5. India market size and forecast
7.4.6. Australia market size and forecast
7.4.7. South Korea market size and forecast
7.4.8. Taiwan market size and forecast
7.4.9. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends and opportunities
7.5.2. Market size and forecast
7.5.3. Brazil market size and forecast
7.5.4. Turkey market size and forecast
7.5.5. Saudi Arabia market size and forecast
7.5.6. South Africa market size and forecast
7.5.7. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. AUTOLUS LIMITED

8.1.1. Company overview
8.1.2. Company snapshot

8.2. BELLICUM PHARMACEUTICALS, INC.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Clinical trials
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. CELL MEDICA LIMITED

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Clinical trials
8.3.5. Key strategic moves and developments

8.4. ELI LILLY AND COMPANY

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Clinical trials
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. GILEAD SCIENCES, INC. (KITE PHARMA INC.)

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Clinical trials
8.5.5. Business performance

8.6. JUNO THERAPEUTICS, INC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Clinical trials
8.6.4. Business performance
8.6.5. Key strategic moves and developments

8.7. NOVARTIS AG

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Clinical trials
8.7.5. Business performance

8.8. OXFORD BIOMEDICA PLC

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Clinical trials
8.8.5. Business performance

8.9. PFIZER INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Clinical trials
8.9.5. Business performance

8.10. PRECISION BIOSCIENCES INC.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Key strategic moves and developments

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る